Foundation Medicine and Its Collaborators Announce Acceptance of 21 Abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting May 26, 2023 07:05AM
Genentech Data Highlights Strength of Ophthalmology Portfolio and Commitment to Advancing Eye Care at ARVO 2023 Apr 13, 2023 01:00AM
Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain Mar 2, 2023 07:00AM
Spark Therapeutics Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A Dec 12, 2022 12:00PM
Jnana Therapeutics Announces Second Collaboration with Roche to Address Challenging-to-Drug Targets in Cancer, Immune-Mediated and Neurological Diseases Nov 15, 2022 06:00AM
View Older Stories

Nov 3, 2022 09:00AM Genentech to Present Data at ASH 2022 Showcasing Strength of Hematology Portfolio and Expanding Into New Areas to Address More Patient Needs
Oct 19, 2022 01:00AM Genentech to Present New Ocrevus (ocrelizumab) Data in Multiple Sclerosis and Continued Research Into Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2022
Feb 23, 2022 10:29AM Spark Therapeutics Announces Departure of CEO and Founder Jeff Marrazzo; COO Ron Philip Named as Successor
Dec 20, 2021 07:05AM Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies
Dec 17, 2021 08:00AM Spark Therapeutics to Invest $575M in New 500k Square Foot State-of-the-Art Gene Therapy Innovation Center on Drexel’s University City Campus
Dec 14, 2021 09:00AM Genentech’s Polivy Combination Reduced the Risk of Disease Worsening or Death by 27% in People With Previously Untreated Aggressive Form of Lymphoma
Dec 11, 2021 08:30AM Genentech Presents Pivotal Data at ASH 2021 for Novel Cancer Immunotherapy Mosunetuzumab
Dec 7, 2021 07:55AM Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology, Advancing Novel Medicines to Patients Using Machine Learning and High Content Screening Method
Nov 23, 2021 09:15AM Genentech to Present New Pivotal Data at ASH 2021 From Broad and Comprehensive Portfolio, Challenging Treatment Standards for People With Blood Disorders
Nov 17, 2021 05:01PM Spark Therapeutics Updated SPK-8011 Data from Phase 1/2 Study Shows Multi-Year, Durable Factor VIII (FVIII) Expression that Significantly Reduced Bleeding in Hemophilia A Patients
Oct 5, 2021 01:00AM Genentech to Present New Data on Ocrevus (ocrelizumab) in Multiple Sclerosis and Enspryng (satralizumab-mwge) in Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2021
Sep 7, 2021 01:00AM Genentech to Present Data From Industry-Leading Portfolio at ESMO 2021 Showing Significant Progress in Early Stage and Uncommon Cancers
Sep 7, 2021 12:00AM NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease
Jul 7, 2021 07:00AM Former Magenta Therapeutics and Foundation Medicine CFO Jason Ryan to Join Sema4 Board of Directors
Jun 4, 2021 08:00AM Genentech Presents Latest Advances With Immunotherapies in Non-Hodgkin’s Lymphoma
May 11, 2021 01:00AM Genentech to Present Data From One of the Most Comprehensive Oncology Portfolios at the 2021 ASCO Annual Meeting Showcasing Advancements for People Living With Cancer
Apr 13, 2021 08:30AM Spark Therapeutics Enters Collaboration with Senti Bio to Bolster Industry-Leading Gene Therapy Research Platform
Apr 13, 2021 08:30AM Senti Bio Enters Collaboration with Spark Therapeutics to Develop Next-Generation Precision Gene Therapies
Feb 25, 2021 07:30AM Spark Therapeutics Further Strengthens Technical Expertise with Appointment of Cynthia Pussinen as Chief Technical Officer
Feb 5, 2021 10:51AM Spark Therapeutics Announces Preliminary Data from Phase 1/2 Clinical Trial of SPK-8016 in Hemophilia A at EAHAD 2021 Virtual Congress
Feb 1, 2021 07:30AM Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease
Nov 16, 2020 07:30AM Spark Therapeutics Expands Visionary Leadership with Appointment of Michael Retterath as Chief Strategy Officer
Nov 5, 2020 09:00AM Genentech to Present New Data Across 16 Blood Disorders at the American Society of Hematology 2020 Annual Meeting
Oct 12, 2020 07:03AM Roche Selects Veeva Development Cloud Applications
Oct 12, 2020 07:03AM Roche Selects Veeva Development Cloud Applications
Sep 3, 2020 01:00AM Genentech to Present New Data in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder at MSVirtual2020
Aug 10, 2020 07:30AM Spark Therapeutics Deepens Drug Development Expertise in Hematology and Rare Disease with Appointment of Gallia G. Levy, M.D., Ph.D., as Chief Medical Officer
Jul 12, 2020 10:15AM Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1/2 Clinical Trial in Hemophilia A at ISTH 2020 Virtual Congress
May 7, 2020 01:00AM New Data at the ASCO20 Virtual Scientific Program Reflects Genentech’s Commitment to Accelerating Progress in Cancer Care
Feb 13, 2020 01:00AM Foundation Medicine and Chugai Announce Partnership with National Cancer Center for the Use of FoundationOne®Liquid in the Third Stage of SCRUM-Japan
Oct 14, 2019 08:00AM Roche Partners with iHeartMedia to Present 'iHeartCountry One Night For Our Military' Concert to Bring Further Awareness of The Impact Diabetes Has On The Nation's Veteran Population
Sep 30, 2019 02:30AM Genentech to Present Results of First Prospective Trial Using Blood-based Next Generation Sequencing Which Successfully Identifies People for Treatment With Alecensa (Alectinib)
Sep 13, 2019 01:03AM Genentech Presents New Six-year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation and Continuation of Treatment Reduced Disability Progression in Multiple Sclerosis
Sep 10, 2019 01:00AM Genentech Presents New Ocrevus (Ocrelizumab) Biomarker Data That Increase Understanding of Disease Progression in Multiple Sclerosis at ECTRIMS
Sep 4, 2019 01:00AM Genentech to Present Pivotal Data for Satralizumab in Neuromyelitis Optica Spectrum Disorder and Six-year Ocrevus (Ocrelizumab) Data in Multiple Sclerosis at ECTRIMS
May 10, 2019 01:00AM Genentech to Present New Data Highlighting Comprehensive Approach to Cancer Care at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
May 8, 2019 01:00AM Genentech to Present New OCREVUS (Ocrelizumab) Data Analyses Showing Significant Reduction of Disability Progression in Relapsing and Primary Progressive Multiple Sclerosis at the AAN Annual Meeting
May 7, 2019 01:00AM Genentech Presents Data from the Risdiplam Pivotal FIREFISH and SUNFISH Studies in Spinal Muscular Atrophy at the 2019 AAN Annual Meeting
Apr 29, 2019 01:00AM New Genentech Data at the 2019 AAN Annual Meeting Showcase Breadth and Promise of Neuroscience Portfolio
Mar 28, 2019 03:00AM The EIU's Index of Cancer Preparedness reveals huge gaps in health system readiness and governance
Dec 27, 2018 08:00AM Foundation Medicine Announces Regulatory Approval of FoundationOne®CDx in Japan
Dec 4, 2018 07:03AM Veeva Vault PromoMats Selected by Roche for Digital Asset Management and Content
Dec 4, 2018 07:03AM CORRECTING and REPLACING Veeva Vault PromoMats Selected by Roche for Digital Asset Management and Content
Dec 4, 2018 05:00AM Veeva Vault PromoMats selected by Roche for Digital Asset Management and Content
Nov 1, 2018 12:35PM Genentech to Present New Data from Its Industry-Leading Hematology Portfolio at the American Society of Hematology (ASH) 2018 Annual Meeting
Oct 27, 2018 10:20AM New Stairway Study Data Shows Potential for Extended Durability with Faricimab in Wet Age-Related Macular Degeneration (AMD)
Oct 21, 2018 05:00AM Genentech’s Investigational Personalized Medicine Entrectinib Shrank Tumors in People with NTRK Fusion-Positive Solid Tumors
Oct 12, 2018 12:30AM Chugai Releases Disease Awareness Anime about Rheumatoid Arthritis in Multiple Languages Emphasizing Importance of Early Detection/Treatment and Care by Specialists
Oct 10, 2018 01:00AM OCREVUS (Ocrelizumab) Data Show Early Initiation of Treatment Reduces Disability Progression Over Five Years in Relapsing and Primary Progressive Multiple Sclerosis
Oct 9, 2018 01:00AM Genentech to Present New Positive Data from Its Broad Cancer Immunotherapy Program and across a Wide Range of Cancers at the European Society for Medical Oncology (ESMO) 2018 Congress
View Older Stories